What is Opsoclonus myoclonus syndrome

Opsoclonus myoclonus syndrome (OMS), sometimes called "dancing eye syndrome," is a rare, immune-mediated neurological disorder characterized by involuntary, erratic eye movements (opsoclonus) and sudden, brief muscle jerks (myoclonus). It is often triggered by an underlying post-viral immune response or, particularly in children, an associated tumor such as a neuroblastoma.

What are the symptoms and body systems affected by Opsoclonus myoclonus syndrome?

Opsoclonus myoclonus syndrome primarily affects the central nervous system, specifically the cerebellum and the brainstem areas that control eye movement and motor coordination. Patients typically experience a triad of symptoms: chaotic, multidirectional eye oscillations (opsoclonus), rapid muscle jerking (myoclonus), and generalized body instability (ataxia). Beyond these core neurological features, individuals with Opsoclonus myoclonus syndrome may also experience significant behavioral changes, irritability, sleep disturbances, and developmental regression in pediatric cases. Because the condition is driven by an immune attack on the nervous system, these symptoms can appear rapidly, often over the course of a few days or weeks.

Who is typically affected by Opsoclonus myoclonus syndrome?

Opsoclonus myoclonus syndrome is exceptionally rare, with an estimated incidence of approximately 1 in 5,000,000 people per year. While it can occur at any age, it is most frequently diagnosed in young children, with a median age of onset around 18 to 20 months. Research indicates that approximately 50% of pediatric cases of Opsoclonus myoclonus syndrome are associated with an underlying neuroblastoma, a type of nerve tissue cancer. In adults, the condition is less frequently linked to malignancy and is more often considered a paraneoplastic syndrome (associated with breast or lung cancer) or a post-viral inflammatory response. There is no known geographic or ethnic predisposition, and it affects both males and females.

How does the body's immune system trigger Opsoclonus myoclonus syndrome?

The underlying mechanism of Opsoclonus myoclonus syndrome is believed to be an autoimmune process. The body mistakenly produces antibodies that target neurons in the cerebellum. This "molecular mimicry" often begins when the immune system attempts to fight off a viral infection or, in some cases, a tumor. The resulting inflammation disrupts the neural pathways responsible for smooth eye movements and motor control. Because this is an immune-mediated condition, the goal of medical intervention is typically to suppress the overactive immune response using corticosteroids, intravenous immunoglobulin (IVIG), or other immunosuppressive therapies.

Key facts to help differentiate Opsoclonus myoclonus syndrome

Distinguishing Opsoclonus myoclonus syndrome from other movement disorders is critical for effective treatment. Key differentiating factors include:

• Eye movement pattern: Unlike nystagmus, which is rhythmic, opsoclonus is characterized by chaotic, non-rhythmic, conjugate, and multidirectional eye movements.


• Association with neuroblastoma: The presence of a neuroblastoma is a hallmark feature in children that distinguishes Opsoclonus myoclonus syndrome from other pediatric encephalopathies.


• Rapid onset: Symptoms of Opsoclonus myoclonus syndrome often appear acutely, whereas many other neurological degenerative diseases have a more gradual, progressive onset.

Next steps

• Consult a pediatric or adult neurologist immediately if you suspect Opsoclonus myoclonus syndrome, as early treatment is associated with better long-term outcomes.


• Request a comprehensive work-up, including an MRI of the brain and imaging (such as MIBG scans or CT/MRI) to rule out underlying tumors.


• Connect with the 7 members of the DiseaseMaps.org community who have navigated this diagnosis to share experiences and coping strategies.


• Seek specialized care at a tertiary medical center with experience in neuro-immunology.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding a medical condition.

References

• Orphanet: Opsoclonus-myoclonus syndrome (ORPHA:2758)


• NIH Genetic and Rare Diseases Information Center (GARD): Opsoclonus myoclonus syndrome


• OMIM (Online Mendelian Inheritance in Man): Entry #164050 (Opsoclonus-myoclonus)


• National Institute of Neurological Disorders and Stroke (NINDS): Opsoclonus Myoclonus Syndrome Information Page